Literature DB >> 8173037

Cytology of bronchoalveolar lavage in some rare pulmonary disorders: pulmonary alveolar proteinosis and amiodarone pulmonary toxicity.

M Mermolja1, T Rott, A Debeljak.   

Abstract

Cytological patterns of bronchoalveolar lavage (BAL) in pulmonary alveolar proteinosis (PAP) and amiodarone pulmonary toxicity (APT) are presented together with light and electron microscopy (EM). The differential cell count of BAL in both diseases is similar in that alveolar macrophages predominate. However, the cytology of PAP is characterized by scanty macrophages and alveolar epithelial cells in abundant periodic acid-Schiff (PAS)-positive extracellular material. The gross appearance of the BAL fluid is therefore opaque. In contrast, the cytology of APT is characterized by foamy alveolar macrophages with numerous lamellar bodies in their cytoplasm, and the BAL fluid is clear.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8173037     DOI: 10.1111/j.1365-2303.1994.tb00122.x

Source DB:  PubMed          Journal:  Cytopathology        ISSN: 0956-5507            Impact factor:   2.073


  4 in total

Review 1.  Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis.

Authors:  P L Shah; D Hansell; P R Lawson; K B Reid; C Morgan
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

2.  Acute respiratory failure caused by secondary alveolar proteinosis in a patient with acute myeloid leukemia: a case report.

Authors:  A Gacouin; Y Le Tulzo; E Suprin; E Briens; M Bernard; C Camus; R Thomas
Journal:  Intensive Care Med       Date:  1998-03       Impact factor: 17.440

3.  Pulmonary alveolar proteinosis: diagnosis using routinely processed smears of bronchoalveolar lavage fluid.

Authors:  T Mikami; Y Yamamoto; M Yokoyama; I Okayasu
Journal:  J Clin Pathol       Date:  1997-12       Impact factor: 3.411

Review 4.  Amiodarone: review of pulmonary effects and toxicity.

Authors:  Spyros A Papiris; Christina Triantafillidou; Likurgos Kolilekas; Despoina Markoulaki; Effrosyni D Manali
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.